2012 Annual Report  Estimated End-User Demand  13  $^{ }$Fervex, a cold and flu product, had 2.9 months of inventory on hand internationally at direct customers compared to 5.3 months of  inventory on hand at December 31, 2011. The level of inventory on hand decreased following the peak of flu season, with the  remaining inventory on hand primarily attributable to ordering patterns of pharmacists in France.  Dafalgan , an analgesic product sold principally in Europe, had 1.1 months of inventory on hand at direct customers compared to 1.0  months of inventory on hand at December 31, 2011. The level of inventory on hand was primarily due to ordering patterns of  pharmacists in France.  $^{ }$Avapro / Avalide  had 1.9 months of inventory on hand in the U.S. compared to 0.6 of inventory on hand at December 31, 2011 due to  the loss of exclusivity in March 2012 and a one-time increase of $3 million of inventory in the wholesale and retail distribution  channels corresponding with the transition of  Avapro / Avalide  manufacturing to Sanofi pursuant to the restructured agreement. Levels of inventory on hand in the wholesale and retail distribution channels were considered in assessing the sales return reserves  established as of December 31, 2012.  Plavix  had 1.3 months of inventory on hand in the U.S. compared to 0.5 months of inventory on hand at December 31, 2011 due to  the loss of exclusivity in May 2012. We expect a gradual decrease in inventory on hand of  Plavix  to occur over the next few years  as product in the wholesale distribution channel continues to be worked down or returned. Levels of inventory on hand in the  wholesale and retail distribution channels were considered in assessing the sales return reserves established as of December 31,  2012.  Pursuant to the U.S. Securities and Exchange Commission (SEC) Consent Order described below under "—SEC Consent Order", we  monitor the level of inventory on hand in the U.S. wholesaler distribution channel and outside of the U.S. in the direct customer  distribution channel. We are obligated to disclose products with levels of inventory in excess of one month on hand or expected  demand, subject to a de minimis exception. Estimated levels of inventory in the distribution channel in excess of one month on hand  for these products were not material as of the dates indicated above. Below are U.S. products that had estimated levels of inventory in  the distribution channel in excess of one month on hand at December 31, 2012, and international products that had estimated levels of  inventory in the distribution channel in excess of one month on hand at September 30, 2012.  ** Change in excess of 100%. (a) The  Sustiva  Franchise includes sales of  Sustiva , as well as revenue of bulk efavirenz included in the combination therapy  Atripla . The months on hand relates  only to  .  (b) Erbitux ,  Yervoy  and  Nulojix  are parenterally administered products and do not have prescription-level data as physicians do not write prescriptions for these  products.  (c) Orencia  intravenous formulation is a parenterally administered product and does not have prescription-level data as physicians do not write prescriptions for this  product. The  Orencia  subcutaneous formulation ( Orencia SC ) is not parenterally administered and was launched in the U.S. in the fourth quarter of 2011. Orencia SC  sales were $201 million in 2012 and $15 million in 2011.  (d) Yervoy  and  Nulojix  were launched in the U.S. in the second quarter of 2011.  (e) Byetta Bydureon  net sales are included in our results following the completion of our acquisition of Amylin in the third quarter of 2012.  $^{ }$The following tables set forth for each of our key products sold in the U.S. for the years ended December 31, 2012, 2011 and 2010: (i)  change in reported U.S. net sales for each year; (ii) estimated total U.S. prescription change for the retail and mail order channels  calculated by us based on third-party data on a weighted-average basis, and (iii) months of inventory on hand in the wholesale  distribution channel.  Year Ended December 31, At December 31,  Change in U.S. % Change in U.S.  Net Sales Total Prescriptions  Months on Hand  Dollars in Millions 2012  2011 2012 2011 2012 2011 2010 Plavix  (64)% 8 %  (60)%  (5)%  1.3   0.5   0.5  Avapro / Avalide  (72)%  (19)%  (71)%  (39)%  1.9   0.6   0.4  Abilify 2 % 4 % 1 % 5 %  0.4   0.5  Reyataz 1  (5)% 2  0.5   0.5  Sustiva  Franchise$^{(a)}$  7 % 7 %  (1)% 7 %  0.6   0.6   0.4  Baraclude 16 16 11 % 9  0.5   0.6  Erbitux $^{(b)}$  1 % 4 % N/A  N/A  0.6   0.6   0.5  Sprycel 35 57 29 % 30 %  0.7   0.7   0.6  Yervoy $^{(b)(d)}$  56 % N/A  N/A  N/A  0.6   0.6  N/A Orencia $^{(c)}$  28 13 % N/A  0.5   0.5   0.6  Nulojix $^{(b)(d)}$  **  N/A  N/A  N/A  0.9   3.5  N/A Onglyza/Kombiglyze 49 % **  47 % **  0.5   0.5   0.8  Byetta $^{(e)}$  N/A  N/A  N/A  N/A  0.8  N/A N/A Bydureon $^{(e)}$  N/A  N/A  N/A  N/A  0.8  N/A N/A